- Home
- SRRK vs OUT Comparison
SRRK vs OUT Comparison
Compare SRRK & OUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRRK | OUT |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 5.5B |
| IPO Year | 2018 | 2013 |
Fundamental Metrics
Financial Performance| Metric | SRRK | OUT |
|---|---|---|
| Price | $48.62 | $32.72 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 18 | 6 |
| Target Price | ★ $70.44 | $37.60 |
| AVG Volume (30 Days) | ★ 1.6M | 1.5M |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | ★ 4.22% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.91 |
| Revenue | N/A | ★ $1,831,700,000.00 |
| Revenue This Year | N/A | $9.18 |
| Revenue Next Year | $2,397.26 | $2.74 |
| P/E Ratio | ★ N/A | $34.48 |
| Revenue Growth | N/A | ★ 0.04 |
| 52 Week Low | $29.35 | $21.28 |
| 52 Week High | $61.76 | $34.96 |
Technical Indicators
Market Signals| Indicator | SRRK | OUT |
|---|---|---|
| Relative Strength Index (RSI) | 59.16 | 61.81 |
| Support Level | $45.82 | $31.11 |
| Resistance Level | $50.29 | $33.71 |
| Average True Range (ATR) | 2.31 | 1.00 |
| MACD | 1.10 | -0.05 |
| Stochastic Oscillator | 67.28 | 91.78 |
Price Performance
Historical ComparisonAbout SRRK Scholar Rock Holding Corporation
Scholar Rock Holding Corp is a biopharmaceutical company focused on improving the lives of children and adults with Spinal Muscular Atrophy and other rare, severe, and debilitating neuromuscular diseases. Its pipeline candidates include apitegromab and a subcutaneous formulation of apitegromab. The clinical-stage pipeline also includes SRK-439, an investigational subcutaneously administered fully human anti-pro/latent myostatin antibody with high inhibitory potency and selectivity toward myostatin, being developed for the treatment of rare neuromuscular diseases. The company also maintains early-stage programs focused on therapies for rare, severe, and debilitating neuromuscular diseases.
About OUT OUTFRONT Media Inc.
Outfront Media Inc is a real estate investment trust involved in the ownership of advertising space on its portfolio of billboards and transit displays. The company has two reportable operating segments: Billboard and Transit. It derives maximum revenue from Billboard Segment. The company geographically operates in United States and Canada, of which United States derive maximum revenue.